Page 77 - Human Use News Today

European Medicines Agency validates marketing authorisation application for Jemperli plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer ... | April 25, 2023

The European Medicines Agency has validated a type II variation for potential approval of dostarlimab in combination with carboplatin and paclitaxel for the treatment of patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Last year in the United States, the topical JAK inhibitor became the first repigmentation treatment approved by the FDA for nonsegmental vitiligo, the most common form of the disease.

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for

Opzelura (ruxolitinib) Cream is the first approved treatment in the European Union (EU) to address repigmentation in non-segmental vitiligo Phase 3 data supporting the approval show treatment

Opzelura® Cream is the first approved treatment in the European Union to address repigmentation in non-segmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura... | April 20, 2023

Prior knowledge, platforms, parallel backup programs, and strategic timing all come into play when rapidly scaling up a mAbs development program in...

This randomized clinical trial assesses the effect of adding panitumumab vs bevacizumab to standard first-line chemotherapy on overall survival among patients w

MASTER TECHNOLOGY TRANSFER, MANUFACTURING AND CLINICAL SUPPLY SERVICES AGREEMENT FOR BCMA CAR-T PRODUCT This Master Technology Transfer, Manufacturing and Clinical Supply... | April 14, 2023

The Pharmaceutical Journal from the Royal Pharmaceutical Society